Racial disparity in esophageal squamous cell carcinoma treatment and survival in the united states

Esophageal squamous cell carcinoma (ESCC) has a higher incidence and prevalence than esophageal adenocarcinoma amongst Black individuals in the United States. Black individuals have lower ESCC survival. These racial disparities have not been thoroughly investigated. We examined the disparity in treatment and survival stratified by ESCC stage at diagnosis.The Surveillance, Epidemiology, and End Results database was queried to identify patients with ESCC between 2000-2019. The identified cohort was divided into subgroups by race. Patient and cancer characteristics, treatment received, and survival rates were compared across the racial subgroups.A total of 23,768 patients with ESCC were identified. Compared with White individuals, Black individuals were younger and had more distant disease at the time of diagnosis (distant disease: 26.7% vs. 23.8%, p<0.001). Black individuals had lower age-standardized 5-year survival for localized (Survival % [95% CI]: 19.3 [16 - 22.8] vs. 27.6 [25.1 - 30.2]), regional (14.3 [12 - 16.7] vs. 21.1 [19.6 - 22.7]), and distant (2.9 [1.9 - 4.1] vs. 6.5 [5.5 - 7.5]) disease. Black individuals were less likely to receive chemotherapy (54.7% vs. 57.5%, p=0.001), radiation (58.5% vs. 60.4%, p=0.03), and surgery (11.4% vs 16.3%, p<0.0001).Black individuals with ESCC have a lower survival than White individuals. This could be related to presenting at a later stage, but also disparities in which treatments they receive even among individuals with the same stage of disease. To what extent these disparities in receipt of treatment is due to structural racism, social determinants of health, implicit bias, or patient preferences deserves further study.